Shares of Gland Pharma declined 2.02% to Rs 1,981 at 12:14 pm on Wednesday. The stock is among the top losers on the Nifty Midcap 150 index.
Financial Snapshot:
Gland Pharma's consolidated revenue for the quarter-ending June 2025 stood at Rs 1,505.62 Crore, up from Rs 1,424.91 Crore in the quarter-ending March 2025. Net profit for the same period was Rs 215.48 Crore, compared to Rs 186.54 Crore in the previous quarter. The company's EPS for June 2025 was Rs 13.08, up from Rs 11.32 in March 2025.
The company’s consolidated revenue for the year-ending March 2025 was Rs 5,616.50 Crore. The net profit for the year-ending March 2025 stood at Rs 698.53 Crore, and the Earnings Per Share (EPS) was Rs 42.40. The book value per share (BVPS) was Rs 555.40 and the return on equity (ROE) was 7.63% and debt to equity was 0.03.
Quarterly Financial Performance (Consolidated):
| Heading | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 1,401.71 Crore | Rs 1,405.83 Crore | Rs 1,384.05 Crore | Rs 1,424.91 Crore | Rs 1,505.62 Crore |
| Net Profit | Rs 143.76 Crore | Rs 163.53 Crore | Rs 204.69 Crore | Rs 186.54 Crore | Rs 215.48 Crore |
| EPS | 8.73 | 9.93 | 12.42 | 11.32 | 13.08 |
Yearly Financial Performance (Consolidated):
| Heading | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 3,462.88 Crore | Rs 4,400.71 Crore | Rs 3,624.60 Crore | Rs 5,664.72 Crore | Rs 5,616.50 Crore |
| Net Profit | Rs 996.96 Crore | Rs 1,211.66 Crore | Rs 781.04 Crore | Rs 772.46 Crore | Rs 698.53 Crore |
| EPS | 63.07 | 73.81 | 47.44 | 46.90 | 42.40 |
| BVPS | 360.86 | 435.64 | 483.23 | 529.65 | 555.40 |
| ROE | 16.88 | 16.92 | 9.81 | 8.85 | 7.63 |
| Debt to Equity | 0.00 | 0.00 | 0.00 | 0.04 | 0.03 |
Yearly Standalone Income Statement:
| Header | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
| Sales | 4,116 | 4,167 | 3,616 | 4,400 | 3,462 |
| Other Income | 215 | 166 | 240 | 223 | 134 |
| Total Income | 4,331 | 4,334 | 3,856 | 4,624 | 3,597 |
| Total Expenditure | 2,842 | 2,920 | 2,801 | 3,000 | 2,259 |
| EBIT | 1,488 | 1,413 | 1,055 | 1,624 | 1,338 |
| Interest | 22 | 7 | 7 | 5 | 3 |
| Tax | 375 | 362 | 272 | 406 | 337 |
| Net Profit | 1,089 | 1,043 | 775 | 1,212 | 997 |
| Header | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
| Operating Activities | 1,073 | 1,135 | 367 | 791 | 604 |
| Investing Activities | 1,578 | -2,923 | 1,208 | -1,010 | -1,524 |
| Financing Activities | -339 | -7 | 14 | 34 | 1,238 |
| Others | 4 | 6 | 3 | 3 | 3 |
| Net Cash Flow | 2,316 | -1,789 | 1,594 | -180 | 322 |
| Header | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
| Share Capital | 16 | 16 | 16 | 16 | 16 |
| Reserves & Surplus | 9,738 | 8,977 | 7,935 | 7,141 | 5,886 |
| Current Liabilities | 523 | 414 | 730 | 581 | 512 |
| Other Liabilities | 142 | 132 | 91 | 94 | 80 |
| Total Liabilities | 10,421 | 9,541 | 8,773 | 7,834 | 6,496 |
| Fixed Assets | 1,787 | 1,813 | 1,747 | 1,692 | 1,292 |
| Current Assets | 5,766 | 4,571 | 6,888 | 5,844 | 5,123 |
| Other Assets | 2,867 | 3,156 | 137 | 296 | 80 |
| Total Assets | 10,421 | 9,541 | 8,773 | 7,834 | 6,496 |
| Contingent Liabilities | 114 | 100 | 128 | 124 | 219 |
| Ratio | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
| Basic EPS (Rs.) | 66.15 | 63.35 | 47.12 | 73.84 | 63.07 |
| Diluted Eps (Rs.) | 66.15 | 63.35 | 47.11 | 73.67 | 62.99 |
| Book Value /Share (Rs.) | 592.08 | 546.13 | 482.90 | 435.68 | 360.86 |
| Dividend/Share (Rs.) | 18.00 | 20.00 | 0.00 | 0.00 | 0.00 |
| Face Value | 1 | 1 | 1 | 1 | 1 |
| Gross Profit Margin (%) | 40.27 | 37.80 | 34.81 | 39.41 | 41.49 |
| Operating Margin (%) | 36.16 | 33.91 | 30.75 | 36.90 | 38.64 |
| Net Profit Margin (%) | 26.47 | 25.03 | 21.45 | 27.54 | 28.79 |
| Return on Equity (%) | 11.17 | 11.59 | 9.75 | 16.93 | 16.88 |
| ROCE (%) | 15.03 | 15.48 | 13.82 | 22.39 | 22.36 |
| Return On Assets (%) | 10.45 | 10.93 | 8.84 | 15.47 | 15.34 |
| Current Ratio (X) | 11.01 | 11.04 | 9.43 | 10.04 | 10.00 |
| Quick Ratio (X) | 8.62 | 7.99 | 6.77 | 8.01 | 7.51 |
| Debt to Equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratios (X) | 72.59 | 200.87 | 169.82 | 331.03 | 392.34 |
| Asset Turnover Ratio (%) | 0.41 | 0.46 | 0.44 | 0.61 | 53.30 |
| Inventory Turnover Ratio (X) | 3.27 | 2.60 | 1.10 | 1.66 | 2.72 |
| 3 Yr CAGR Sales (%) | -3.29 | 9.70 | 17.19 | 46.72 | 46.21 |
| 3 Yr CAGR Net Profit (%) | -5.18 | 2.30 | 0.19 | 63.78 | 76.21 |
| P/E (x) | 24.07 | 29.13 | 26.92 | 44.32 | 39.29 |
| P/B (x) | 2.69 | 3.37 | 2.63 | 7.50 | 6.87 |
| EV/EBITDA (x) | 14.36 | 18.24 | 13.61 | 29.19 | 26.12 |
| P/S (x) | 6.37 | 7.28 | 5.78 | 12.21 | 11.71 |
Gland Pharma announced an investor meet, according to a BSE filing on September 8, 2025. The company also announced the reappointment of Mr. Essaji Goolam Vahanvati as an Independent Director on August 28, 2025. Additionally, there was an appointment of Secretarial Auditors on August 28, 2025.
The company announced a final dividend of Rs 18 per share with effective date as August 14, 2025 and announced date as May 20, 2025. Prior to this, a final dividend of Rs 20 per share was announced May 22, 2024, with effective date as August 16, 2024.
Moneycontrol analysis, as of September 11, 2025, indicates a very bullish sentiment on the stock.
With the stock's last traded price at Rs 1,981, Gland Pharma has seen a decline of 2.02% from its previous close.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
